In this episode of TOGA's Conversations in Lung Cancer Research, host Dr. Samantha Bowyer (Sir Charles Gairdner Hospital, Perth), alongside A/Prof Rachel Roberts-Thomson (The Queen Elizabeth Hospital, Adelaide) and A/Prof Abhijit Pal (Liverpool and Bankstown Hospitals, Sydney), examine the emerging role of bispecific antibodies in thoracic oncology. The panel explores how these multiple-targeting engineered molecules differ from standard monoclonal antibodies to overcome primary and acquired immunotherapy resistance, detailing key classes in development including dual receptor blockers like amivantamab, T-cell engagers like tarlatamab, and PD-(L)1 × VEGF bispecifics like ivonescimab, PF-08634404 and pumitamig. Drawing on clinical trial and real-world experience, the guests discuss the operational logistics and unique toxicity profiles associated with these agents, such as infusion reactions, dermatologic side effects, and bleeding risks, while evaluating the shift of bispecific antibodies into first-line and early-stage treatment strategies.
In this episode of TOGA's Conversations in Lung Cancer Research, host Dr. Samantha Bowyer (Sir Charles Gairdner Hospital, Perth), alongside A/Prof Rachel Roberts-Thomson (The Queen Elizabeth Hospital, Adelaide) and A/Prof Abhijit Pal (Liverpool and Bankstown Hospitals, Sydney), examine the emerging role of bispecific antibodies in thoracic oncology. The panel explores how these multiple-targeting engineered molecules differ from standard monoclonal antibodies to overcome primary and acquired immunotherapy resistance, detailing key classes in development including dual receptor blockers like amivantamab, T-cell engagers like tarlatamab, and PD-(L)1 × VEGF bispecifics like ivonescimab, PF-08634404 and pumitamig. Drawing on clinical trial and real-world experience, the guests discuss the operational logistics and unique toxicity profiles associated with these agents, such as infusion reactions, dermatologic side effects, and bleeding risks, while evaluating the shift of bispecific antibodies into first-line and early-stage treatment strategies.
This podcast was proudly sponsored by Pfizer. All development and editorial decisions were made independently by the speakers.
(00:00) Welcome and Guests
(01:34) What Are Bispecifics?
(03:32) Why Immunotherapy Fails
(05:19) Targets Beyond PD-1
(07:11) Bispecific Classes Overview
(09:17) Real World Experience
(11:13) Clinic Logistics and Safety
(15:00) Efficacy and Trial Data
(18:01) Reprogramming Microenvironment
(21:20) Future Directions and Wrap